In this report, we have studied the immunogenicity of the nominal antigen, carcinoembryonic
antigen (CEA), and that of an anti-idiotype antibody, 3H1, which mimics CEA and can be …

The goal of cancer therapy remains as the long‐term eradication of tumor cells without
adverse effects on normal tissue. Conventional approaches utilizing chemotherapy and …

A genetic vaccine platform based on DNA electroporation (DNA-EP) and adenovirus (Ad)
was used to generate immune response against human carcinoembryonic antigen (CEA) …

In recent years, vaccination strategies using antigen-presenting cells (APC) have been
under investigation. Antigen delivery using genetic immunization through ex vivo …

Carcinoembryonic antigen (CEA) is strongly expressed in a vast majority of gastrointestinal
carcinomas. Recently, epitope peptides of CEA were identified. We have demonstrated HLA …

The carcinoembryonic antigen (CEA) is the main tumor-associated antigen of colorectal
cancers. Previously, we developed a DNA vaccine using scFv6. C4, a CEA surrogate …

Administration of DNA vaccines via gene gun has emerged as an important form of Ag-
specific immunotherapy. The MHC CIITA is a master regulator of MHC class II expression …

Carcinoembryonic antigen (CEA) is intensively studied as a potential target for
immunotherapy of colorectal cancers. Although overexpressed by tumors, CEA is also …

Esophageal squamous cell carcinoma (ESCC) is a highly malignant tumor which usually is
diagnosed in advanced stages due to its asymptomatic course of tumorigenesis. Current …

Pulsing dendritic cells (DCs) with tumor cell-derived mRNA is regarded as an attractive
alternative in the development of DC-based tumor vaccines. Our aim is to improve the …